News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Sanofi-Aventis (France) Settles with Sandoz Pharmaceuticals, Teva Pharmaceutical Industries Limited on Eloxatin Patent
April 1, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- French drugmaker Sanofi-Aventis (SASY.PA) has settled a patent law suit over cancer drug Eloxatin, putting a block on several other drugmakers selling their generic versions from late June until August 2012.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Sanofi
MORE ON THIS TOPIC
Rare diseases
Senator Ron Johnson Launches Investigation Into FDA Rare Disease Rejections
March 10, 2026
·
3 min read
·
Heather McKenzie
Opinion
Direct-to-Consumer Drugs Are Not a Panacea for High Costs
March 6, 2026
·
4 min read
·
Michael Grosberg
Patents
Moderna Notches Much-Needed Win in COVID-19 Patent Spat With Roivant
March 4, 2026
·
2 min read
·
Tristan Manalac
Opinion
Navigating the FDA After the Storm To Advance Drug Candidates
March 3, 2026
·
4 min read
·
John Kirk